BusinessAxsome Therapeutics Reports Fourth Quarter and Full Year 2017 Financial Results and Provides Business UpdateBy Nasdaq OMXMar 7, 2018, 12:01 PM UTC
BusinessAxsome Therapeutics Announces Primary Endpoint Met in Phase 1 Trial of Next Generation Product Candidate AXS-09 Containing Chirally Pure Esbupropion and DextromethorphanBy Nasdaq OMXFeb 26, 2018, 12:00 PM UTC
BusinessAxsome Therapeutics to Present at 2018 BIO CEO & Investor ConferenceBy Nasdaq OMXFeb 5, 2018, 12:00 PM UTC
BusinessAxsome Therapeutics Announces AXS-02 Independent Data Monitoring Committee Recommends Continuation of COAST-1 Trial and Discontinuation of CREATE-1 TrialBy Nasdaq OMXJan 9, 2018, 12:02 PM UTC
BusinessAxsome Therapeutics to Present at Biotech Showcase 2018By Nasdaq OMXDec 19, 2017, 12:01 PM UTC
BusinessAxsome Therapeutics Collaborates with World-Leading Nicotine Addiction Research Center for Phase 2 Trial of AXS-05 in Smoking CessationBy Nasdaq OMXDec 14, 2017, 12:00 PM UTC
BusinessAxsome Therapeutics Reports Third Quarter 2017 Financial ResultsBy Nasdaq OMXNov 8, 2017, 12:01 PM UTC
BusinessAxsome Therapeutics to Present at Upcoming Investor ConferencesBy Nasdaq OMXSep 18, 2017, 11:00 AM UTC
